All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis.

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F25304046%3A_____%2F05%3A%230000001" target="_blank" >RIV/25304046:_____/05:#0000001 - isvavai.cz</a>

  • Result on the web

  • DOI - Digital Object Identifier

Alternative languages

  • Result language

    angličtina

  • Original language name

    Testing of the Biocan B inj. ad us. vet. vaccine and development of the new recombinant vaccine against canine borreliosis.

  • Original language description

    Verification of efficacy of Biocan B inj. ad us. vet. was done by challenge test. Ticks were used as vectors of infection. Formation of OspA specific antibodies and borrelia specific immunoglobulins was measured in canine sera. Tissues were used for detection of borreliae by cultivation method and DFM. Formation of IgG and OspA antibodies after vaccination was observed. Results are presented in the article. Development of new vaccine is based on preparation of recombinant outer surface proteins of B. afzelii, B. burgdorferi and B. garinii origin. Recombinant proteins were expressed in E. coli. Obtained proteins are being tested. Formation of specific antibodies against some recombinant proteins was confirmed. These proteins are suitable candidates forpreparation of vaccine prototype and will be used in challenge tests.

  • Czech name

    Testace vakcíny Biocan B inj. ad us. vet. a vývoj nové rekombinantní vakcíny proti borrelióze psů.

  • Czech description

    Čelenží byla ověřena účinnost vakcíny Biocan B inj. ad us. vet. Jako vektor infekce byla použita klíšťata. V sérech psů byly stanovovány specifické protilátky outer surface proteinu A a specifické borreliové imunoglobuliny. Pro detekci borrelií kultivační metodou a DFM byly použity vzorky tkání. Byla sledována tvorba protilátek IgG a OspA po vakcinaci. Výsledky jsou prezentovány. Vývoj nové vakcíny spočívá v přípravě rekombinantních Osp původu B. afzelii, B. burgdorferi a B. garinii. Rekombinantní proteiny byly produkovány v E. coli. Získané proteiny jsou testovány na myších. Byla potvrzena tvorba specifických protilátek proti některým rekombinantním proteinům. Tyto proteiny jsou vhodnými kandidáty pro přípravu prototypu vakcíny a budou použity v čelenžních testech.

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    EI - Biotechnology and bionics

  • OECD FORD branch

Result continuities

  • Project

    <a href="/en/project/FD-K3%2F100" target="_blank" >FD-K3/100: *Biotechnological production of antigens of Borrelia burgdorferi sensu lato for preparation of prototype of vaccine against Lyme borreliosis.</a><br>

  • Continuities

    P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Others

  • Publication year

    2005

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Biomedical Papers

  • ISSN

    1213-8118

  • e-ISSN

  • Volume of the periodical

    149

  • Issue of the periodical within the volume

    2

  • Country of publishing house

    CZ - CZECH REPUBLIC

  • Number of pages

    6

  • Pages from-to

    297-302

  • UT code for WoS article

  • EID of the result in the Scopus database